Purpose: Volume overload in chronic severe mitral regurgitation causes left atrial remodeling. MV surgery usually results in left atrial (LA) volume reduction. In patients undergoing mitral valve surgery, LA reverse remodeling was related to better postoperative clinical outcome and survival previously. However, only few clinical and echocardiographic parameters were suggested to be associated with LA reverse remodeling. In this study we investigated the relationship between LA peak longitudinal strain (reservoir strain) assessed with 2-dimensional speckle tracking imaging (2D STI) and LA reverse remodeling. Methods: 53 patients (24 females and 29 males, mean age: 45.7±13.5 years) with severe mitral regurgitation and preserved left ventricular systolic function were included in the study. All patients had normal sinus rhythm. The etiology of mitral regurgitation was mitral valve prolapse (MVP) in 37 patients and rheumatic valvular disease in 16 patients. Mitral valve repair was performed in 30 patients while 23 underwent mitral valve replacement. Echocardiography was performed before the surgery and six months later. Left atrial peak longitudinal strain (PLS) was assessed with speckle tracking imaging. LA reverse remodeling was defined as a percent of decrease in LA volume index (LAVI). Results: Left atrial volume index significantly decreased after surgery (58.2±16.6 ml/m 2 vs. 43.9±17.2 ml/m 2 p: < 0.001). Mean LAVI reduction was 22.5% ± 27.2. There was no significant difference in LAVI reduction between mitral repair and replacement groups (22.1±22.6% vs. 23.1±32.8% p: 0.9). Besides decrease in LAVI was also similar in patients with MVP and rheumatic valve disease (24.4±26.8% vs. 18.2±28.9% p: 0.4). Correlates of LAVI reduction were preoperative LAVI (r: 0.28 p: 0.039), LA PLS (r: 0.36 p: 0.001) and age (r: -0.36 p: 0.007). Furthermore, in multivariate linear regression analysis, preoperative LAVI, LA PLS and age were all significant predictors of LA reverse remodeling. Conclusion: Left atrial peak longitudinal strain measured by 2D STI, in conjunction with preoperative LAVI and age is a predictor of LA reverse remodeling in patients undergoing surgery for severe mitral regurgitation. We suggest that in this patient population LA GLS may also be used as a preoperative prognostic marker.
Background: Aortic Stenosis (AS) results in several Left Ventricular (LV) disturbances as well as progressive Left Atrial (LA) enlargement and dysfunction. Transcatheter Aortic Valve Implantation (TAVI) reverses LV remodelling and improves overall systolic function but its effect on LA function remains undetermined. The aim of this prospective study was to investigate the effects of TAVI on LA structure and function. Material and methods: We studied thirty-two patients with severe symptomatic AS and high surgical risk who underwent TAVI, using standard and 2-dimensional speckle-tracking echocardiography before, at 40-day and at 3-month follow-up. Results: Following TAVI, mean transvalvular gradient reduced (p<0.001). Both LA mean area index and LA mean volume index decreased at 40-day (16.2±6.4 Atrial remodelling after TAVI vs. 12.5±2.9 cm 2 /m 2 , and 47.3±12.0 vs. 42.8±12.5 mL/m 2 , respectively, p<0.05) and values remained unchanged at 3 months. The reduction of LA size was accompanied by a significant increase in global PALS (14.4±3.9% vs. 19.1±4.7%, p<0 .001) and global PACS (8.4±2.5% vs. 11.0±4.1%, p<0.05) at 3-month. After the procedure, LA stiffness measurements decreased and became significant at 3-month follow up (p<0.001). Pre-procedural trans-aortic mean gradient and pre-procedural LA volume were identified as predictors of global PALS increase (p<0.0001) while the delta drop in trans-aortic mean gradient as predictors of LA volume index reduction 3 months after TAVI (p<0.0001). Conclusion: TAVI is associated with significant recovery of LA structure and function suggesting a reverse cavity remodelling. Such functional recovery is determined by the severity of pre-procedural valve stenosis. Purpose: Eicosapentaenoic acid (EPA) is a first line drug in the management after myocardial infarction. Mitochondria are major contributors to energy metabolism and recent mounting evidence suggests that mitochondrial dynamics, such as fusion and fission, has a pivotal role in regulating mitochondrial function. This study was designed to determine whether oral EPA mediates mitochondrial fatty acid composition, dynamics, and oxidative phosphorylation, leading to the attenuation of cardiac remodeling after myocardial infarction (MI).
MITOCHONDRIA

Methods and results:
Anterior MI was produced in male rats by ligating the left anterior descending coronary artery (MI group). In the EPA-treated group, EPA (1,000 mg/kg/day) was administrated for 12 weeks after coronary ligation (MI+EPA group). Myocardial infarct size and blood pressure were comparable between groups. At 12 weeks after MI, mitochondria were isolated in non-infarcted myocardium and mitochondrial fatty acid composition was determined using gas chromatography mass spectrometry. In EPA+MI group, mitochondrial EPA content was approximately 10 times higher than that in untreated-MI group. Cardiac function was assessed by echocardiography and 2F micro-manometer-tipped catheter at 12 weeks of MI. EPA significantly improved %fractional shortening, +dP/dt, and -dP/dt, and reduced left ventricular (LV) end-diastolic diameter and pressure. In addition, histological examination showed EPA significantly suppressed myocyte hypertrophy and interstitial fibrosis in non-infarcted myocardium by 15% and 30%, respectively. Levels of ATP in cardiac tissue were measured by highperformance liquid chromatography and mitochondrial oxidative phosphorylation was assessed by O2 consumption using isolated mitochondria. After 12 weeks after MI, ATP contents in non-infarcted myocardium were significantly decreased, and mitochondrial complex II, III, and IV activities were also impaired, while EPA Background: Formation of reactive oxygen species (ROS) contributes to many pathophysiological processes. Although ROS production is also involved in some physiological processes, the imbalance between their generation and removal, i.e. oxidative stress, plays a major role in particular in myocardial injury caused by ischemia-reperfusion (I/R). The mammalian Shc locus encodes three Shc isoforms: p46Shc, p52Shc and p66Shc. The p66Shc is not involved in mitogenic signals as p46Shc/p52Shc, but it functions as a critical mediator of intracellular oxidative signal transduction. Various studies relate p66Shc to cardiovascular disease; however, few data are available on the role of p66Shc in myocardial I/R. Methods and results: 8-12-week-old male p66Shc deficient (p66Shc-/-) mice and corresponding C57Bl/6 wild-type (WT) control mice were subjected in vivo to different durations of ischemia (30, 45 and 60 min) followed by 24h of reperfusion. Infarct size was assessed morphologically and by MRI. After 30 min of ischemia, p66Shc-/-mice developed markedly larger infarcts as compared to WT (infarct size [I]/area at risk [AAR]: 20.46±5.02% vs. 7.72±1.31%, n=12-14, p < 0.05). This effect was confirmed by in vivo silencing of p66Shc prior to I/R. Both genetic deletion and silencing of p66Shc displayed an increased post-ischemic levels of serum cardiac troponin I (cTnI). However, the observed effect on infarct size was limited to 30 min of ischemia since by increasing ischemia duration to either 45 or 60 min infarct size did no longer differ between p66Shc-/-and WT mice. Moreover, differently from WT, infarct size in p66Shc-/-was not significantly larger with increasing duration of ischemia (from 30 to 60 min). On the molecular level the observed effect was linked to the inhibition of activation by phosphorylation of protein kinase Akt and transcription factor STAT3 -two key members of prosurvival pathways RISK and SAFE, respectively. Conclusions: Our data suggest that genetic deletion of p66Shc leads to an increased sensitivity to myocardial infarction with larger infarcts with shorter, but not prolonged ischemia, and that RISK and SAFE prosurvival pathways are involved. Therefore, activation of p66Shc may provide resistance to ischemia and represent a novel therapeutic target in the early phase of myocardial infarction.
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Activation of the mitochondrial ATP-sensitive potassium channel achieves cell protection by promoting re-closure of the mPTP via suppression of GSK-3beta -complex III interaction Purpose: Activation of the mitochondrial ATP-sensitive potassium channel (mKATP) is known to elevate the threshold for opening of the mitochondrial permeability transition pore (mPTP) and to protect cells from ischemia/reperfusion injury. Here we examined the hypothesis that activation of mKATP accelerates re-closure of opened mPTPs, leading to cell survival. Methods and results: H9c2 cells were exposed to antimycin A (AA, 40 μM), a mitochondrial complex III inhibitor that produces excess reactive oxygen species, for 1 hr and then incubated in normal medium for 2 hrs. Mitochondrial membrane potential ( m) was monitored by TMRE, and cell death was determined by LDH measurement at the end of the incubation. Pretreatment with nicorandil (NC, 300 μM), an mKATP activator, did not affect loss of m observed during exposure to AA (38±3% vs. 42±3% of baseline, p=NS) but significantly promoted recovery of m after washout of AA compared with a vehicle (69±3% vs. 51±2%, P<0.01). LDH release was also suppressed by NC (15.7±0.3% vs. 23.2±0.1%, P<0.01). Western blotting revealed that phospho-Ser9 GSK-3β level at 5 min after AA exposure was 34% higher in NC-treated cells than in vehicletreated cells. Inhibition of GSK-3β activity by LiCl (60 mM) mimicked the effects of NC on the recovery of m and suppression of cell death. An inhibitor of the mKATP, 5-hydroxydecanoate (5-HD, 100μM), abolished both GSK-3β phosphorylation and cell protection induced by NC, though the effects of 5-HD were not mimicked by tertiapin Q (100 nM), an inhibitor of renal outer medullary potassium channel (ROMK). Levels of mPTP subunit proteins (i.e., adenine nucleotide translocase, voltage-dependent anion channel and inorganic phosphate carrier) were not altered by exposure to AA, either in the presence or absence of NC. However, protein level of GSK-3β co-immunoprecipitated with Rieske, a subunit of mitochondrial complex III, was significantly increased after treatment with AA by 24%. NC attenuated the interaction between GSK-3β and Rieske. Determination of reactive oxygen species (ROS) by DCF indicated that NC suppressed ROS production during and after AA exposure.
Conclusions:
The results suggest that mKATP activation modifies GSK-3β-complex III interaction by phosphorylation of GSK-3β at Ser9 and that the modified GSK-3β-complex III interaction, presumably via suppressed ROS production, contributes to facilitated re-closure of the mPTP and cell survival.
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Post-ischemic in vivo p66shc silencing as a therapeutical strategy for ischemia/reperfusion brain injury Purpose: Stroke is a leading cause of morbidity and mortality, and its incidence increases with age. Currently, it still lacks a specific therapy for an effective treatment of stroke, thus, new approaches in the treatment are essential. Recently, we demonstrated that p66shc knockout mice are protected from Ischemia/Reperfusion (I/R) brain injury by a decreased production of ROS. The herewith described study was designed to investigate the role of p66shc in stroke in a clinically relevant experimental setup whereby p66shc knockdown is performed after the ischemic episode. Methods: A transient Middle Cerebral Artery Occlusion (MCAO) was performed to induce I/R brain injury in wild type (C57/Bl6) mice. After 45 min of ischemia and directly upon reperfusion, specific small Interfering RNA (siRNA) for p66shc (sip66shc) or scrambled siRNA (siScr) were injected intravenously. 48 h post-MCAO, stroke size and neurological deficit were analyzed using magnetic resonance imaging (MRI) and RotaRod test as well as Bederson test, respectively. Moreover, blood brain-barrier permeability was assessed by measuring Evans blue extravasation. Long-term benefit was studied by analyzing survival up to 6 days. In parallel, to test the human relevance of the data observed in mice, and to characterize the putative protective mechanisms of in vivo p66shc silencing, p66shc silencing was performed on primary Human Brain Endothelial Cells (HBEC) exposed to Hypoxia/Reoxygenation (H/R) and p66shc gene expression was determined in Peripheral Blood Monocytes (PBM) of patients who suffered an ischemic stroke. Results: Post-ischemic in vivo silencing of p66shc resulted in a reduction in stroke size (p<0.01, n=6-7) as well as an improved neurological function (p<0.05, n=11) as compared to siScr injected mice. Moreover, Evans blue extravasation in p66shc silenced mice was reduced as compared to siScr injected mice (p<0.05, n=5-6). Additionally, sip66shc mice displayed a 50% increase in survival 6 days after stroke (p<0.05, n=10-11). In HBEC, H/R increased superoxide anion (O2-) production (p<0.05, n=6) and reduced Nitric Oxide (NO) bioavailability (p<0.01, n=6). Silencing of p66shc blunted H/R-induced O2-generation (p<0.05, n=7) and restored NO bioavailability (p<0.05, n=6). Lastly, in PBM of ischemic stroke patients we found an increased p66shc gene expression as compared to agematched control subjects.
Conclusion:
The present study together with previously published own work underscore the concrete potential for p66shc to become a novel target for the treatment of ischemic stroke and set the basis for follow up clinical studies.
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The cardioprotectant 3',4'-dihydroxyflavonol inhibits the mitochondrial permeability transition pore Purpose: 3',4'-Dihydroxyflavonol (DiOHF) reduces injury caused by myocardial ischaemia and reperfusion (IR) in association with a reduction in oxidative stress. Oxidative stress contributes to the opening of the mitochondrial permeability transition pore (mPTP), a key event in myocardial IR injury. The aim of this study was to determine the effect of DiOHF on mPTP, as well as mitochondrial respiration and the generation of reactive oxygen species (ROS) by cardiac mitochondria after IR in anaesthetised rats. Methods: Male Wistar rats were anaesthetised with pentobarbitone (70 mg/kg iv), intubated and ventilated. Through a left thoracotomy the left main coronary artery was occluded for 30 min and then reperfused for 15 minutes. The heart was then rapidly removed, cooled and the area at risk of ischaemia homogenised and centrifuged for the isolation of mitochondria. In sham experiments the rats were
